GLDC Antibody (A-9): sc-376106
- GLDC Antibody (A-9) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against amino acids 256-555 mapping within an internal region of GLDC of human origin
- recommended for detection of GLDC of mouse, rat and human origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for GLDC Antibody (A-9) for WB applications. These reagents are now offered in bundles with GLDC Antibody (A-9) (see ordering information below).
QUICK LINKS
SEE ALSO...
GLDC Antibody (A-9) is a mouse monoclonal IgG1 antibody that detects GLDC (glycine dehydrogenase) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). GLDC is a crucial component of the glycine cleavage system, which also includes AMT (Protein T), GCSH (Protein H), and DLD (Protein L), and plays a vital role in the degradation of glycine, a key amino acid involved in various metabolic processes. This 1,020 amino acid protein is localized in the mitochondria and belongs to the gcvP family, where GLDC functions by binding glycine and facilitating the transfer of its methylamine group to Protein T. GLDC exists as a homodimer and requires pyridoxal phosphate as a cofactor for enzymatic activity. Proper functioning of GLDC is essential, as mutations in the gene encoding GLDC can lead to nonketotic hyperglycinemia (NKH), a serious autosomal recessive disorder characterized by excessive glycine accumulation in body fluids, resulting in severe neurological symptoms. Anti-GLDC antibody (A-9) is an invaluable tool for researchers studying the glycine cleavage system and its implications in metabolic disorders.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
GLDC Antibody (A-9) References:
- Comprehensive mutation analysis of GLDC, AMT, and GCSH in nonketotic hyperglycinemia. | Kure, S., et al. 2006. Hum Mutat. 27: 343-52. PMID: 16450403
- Genomic deletion within GLDC is a major cause of non-ketotic hyperglycinaemia. | Kanno, J., et al. 2007. J Med Genet. 44: e69. PMID: 17361008
- Epigenetic Silencing of the Putative Tumor Suppressor Gene GLDC (Glycine Dehydrogenase) in Gastric Carcinoma. | Min, HL., et al. 2016. Anticancer Res. 36: 179-87. PMID: 26722042
- The genetic basis of classic nonketotic hyperglycinemia due to mutations in GLDC and AMT. | Coughlin, CR., et al. 2017. Genet Med. 19: 104-111. PMID: 27362913
- Identification and characterization of GLDC as host susceptibility gene to severe influenza. | Zhou, J., et al. 2019. EMBO Mol Med. 11: PMID: 30498026
- GLDC mitigated by miR-30e regulates cell proliferation and tumor immune infiltration in TNBC. | Xie, H., et al. 2022. Front Immunol. 13: 1033367. PMID: 36275705
- gldc Is Essential for Renal Progenitor Patterning during Kidney Development. | Weaver, NE., et al. 2022. Biomedicines. 10: PMID: 36551976
- GLDC promotes colorectal cancer metastasis through epithelial-mesenchymal transition mediated by Hippo signaling pathway. | Yu, H., et al. 2023. Med Oncol. 40: 293. PMID: 37668829
- Glycine Decarboxylase (GLDC) Plays a Crucial Role in Regulating Energy Metabolism, Invasion, Metastasis and Immune Escape for Prostate Cancer. | Chen, MK., et al. 2023. Int J Biol Sci. 19: 4726-4743. PMID: 37781511
- GLDC alleviates cisplatin-induced apoptosis, cellular senescence, and production of reactive oxygen species via regulating UCP1 in the kidney. | Bui, AP., et al. 2025. Life Sci. 368: 123502. PMID: 40010632
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GLDC Antibody (A-9) | sc-376106 | 200 µg/ml | $322.00 | |||
GLDC Antibody (A-9): m-IgG Fc BP-HRP Bundle | sc-540512 | 200 µg Ab; 10 µg BP | $361.00 | |||
GLDC Antibody (A-9): m-IgG1 BP-HRP Bundle | sc-542172 | 200 µg Ab; 20 µg BP | $361.00 |